Dear Sir,<br><br>my first comment is just a technical one, as for the time being the provisional pdf of the article is not accessible.<br><br>Secondly, in the abstract the monoclonal antibody (MAB)Bevacizumab is erroneously described as targeting the human epidermal growth factor receptor (EGFR), while in fact it targets the vascular endothelial growth factor (VEGF) (but not its receptor). The MAB targeting the EGFR is named Cetuximab.<br><br>Yours faithfully<br>Michael Hölling
Targeting EGFR, HER2 and VEGF
23 January 2009
Dear Sir,<br><br>my first comment is just a technical one, as for the time being the provisional pdf of the article is not accessible.<br><br>Secondly, in the abstract the monoclonal antibody (MAB)Bevacizumab is erroneously described as targeting the human epidermal growth factor receptor (EGFR), while in fact it targets the vascular endothelial growth factor (VEGF) (but not its receptor). The MAB targeting the EGFR is named Cetuximab.<br><br>Yours faithfully<br>Michael Hölling
Competing interests
Roche: employee